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Summary
 
Neisseria gonorrhoeae
 
 isolated from patients with disseminated infection are often of the porin
(Por1A) serotype and resist killing by nonimmune normal human serum. The molecular basis
of this resistance (termed stable serum resistance) in these strains has not been fully defined but
is not related to sialylation of lipooligosaccharide. Here we demonstrate that Por1A bearing
gonococcal strains bind more factor H, a critical downregulator of the alternative complement
pathway, than their Por1B counterparts. This results in a sevenfold reduction in C3b, which is
 
.
 
75% converted to iC3b. Factor H binding to isogenic gonococcal strains that differed only in
their porin serotype, confirmed that Por1A was the acceptor molecule for factor H. We identi-
fied a surface exposed region on the Por1A molecule that served as the binding site for factor
H. We used gonococcal strains with hybrid Por1A/B molecules that differed in their surface
exposed domains to localize the factor H binding site to loop 5 of Por1A. This was confirmed
by inhibition of factor H binding using synthetic peptides corresponding to the putative ex-
posed regions of the porin loops. The addition of Por1A loop 5 peptide in a serum bactericidal
assay, which inhibited binding of factor H to the bacterial surface, permitted 50% killing of an
otherwise completely serum resistant gonococcal strain. Collectively, these data provide a mo-
lecular basis to explain serum resistance of Por1A strains of 
 
N
 
.
 
 gonorrhoeae
 
.
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N
 
eisseria gonorrhoeae
 
 elicit a wide range of disease syn-
dromes that range from minimal to severe inflamma-
tion at the local genital site of infection. Gonococci causing
symptomatic local inflammation (pelvic inflammatory dis-
ease, PID)
 
1
 
 are predominantly sensitive to killing in vitro
by nonimmune normal human serum (NHS; reference 1).
In contrast, most gonococci that cause disseminated infec-
tion (DGI) in the absence of local genital symptoms are re-
sistant to NHS killing (2, 3). Most gonococci are pheno-
typically serum resistant when isolated initially, but certain
strains convert to a serum-sensitive phenotype with serial
subculture in vitro (4); others remain stably serum resistant.
Serum resistance of the serum-sensitive phenotype can be re-
stored by the addition of 5
 
9
 
-cytidinemonophospho-
 
N
 
-acetyl
neuraminic acid (CMP-NANA) to the growth medium
(5), which results in sialylation of lipooligosaccharide (LOS;
reference 6). Recent work has defined the mechanism of
this conversion as direct binding of the complement regu-
latory protein factor H to sialylated gonococcal LOS (7).
Functionally, the increase in factor H binding mediates
complete conversion of bound C3b to iC3b and a decrease
in total C3 bound (7; McQuillen, D.P., S. Gulati, S. Ram,
A.K. Turner, D.B. Jani, T.C. Heeren, and P.A. Rice,
manuscript submitted for publication). Stable serum resis-
tance of gonococci, in most cases, also results in increased
conversion of C3b to iC3b but is not explained by sialyla-
tion because many of these strains lack the appropriate ac-
ceptor site on LOS that permits sialylation.
Gonococcal Por, the major outer membrane protein,
occurs in two primary immunochemical classes, Por1A and
Por1B, each composed of multiple serovars (8). Por1A and
Por1B differ in apparent molecular weight, susceptibility to
proteolysis (9), and antibody reactivity (10). In addition to
 
1
 
Abbreviations used in this paper:
 
 CMP-NANA, 5
 
9
 
-cytidinemonophospho-
 
N
 
-acetyl neuraminic acid; DGI, gonococci that cause disseminated infec-
tion; LOS, lipooligosaccharide; NHS, normal human serum; PID, pelvic
inflammatory disease.
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being more highly sensitive to penicillin (11), thiampheni-
col, and rifampin (12), strains expressing Por1A are often
serum resistant and associated with DGI, whereas those ex-
pressing Por1B are more frequently serum sensitive and as-
sociated with PID (13, 14). In contrast to gonococcal LOS,
which exhibits considerable antigenic and phase variation
in vitro (15–17), Por is antigenically stable in vitro (10).
Analysis of the structural genes for Por1A (18) and Por1B
(19) suggests that there is only a single Por structural gene,
composed of two alleles, in the gonococcal genome. This
has been confirmed and hybrid Por1A/B genes have been
constructed by transformation (20).
Microbial factor H–binding proteins that may contribute
to pathogenicity have been identified as the streptococcal
M6 protein (21, 22), the 
 
Yersinia enterocolitica
 
 YadA protein
(23), and the gp41 and gp120 glycoproteins of human im-
munodeficiency virus 1 (24–26). We undertook the cur-
rent study to define whether such a mechanism of serum
resistance might be associated with gonococcal Por1A.
Upon initial screening, we found that nonsialylated Por1A
gonococci bound more factor H in NHS than did Por1B
gonococci. Using isogenic gonococcal strains differing only
in their porin type (27), we demonstrated an association
between the degree of susceptibility to bacterial killing and
the amount of factor H bound. Incubation of purified fac-
tor H with hybrid Por1A/B strains (20) indicated that only
those mutants that contained a region representing loop 5
of Por1A bound factor H. Specificity of factor H binding
was established by inhibition with a synthetic peptide that
corresponded to Por1A loop 5 (28). This peptide was also
able to restore killing in NHS, and thereby confirmed
functional specificity of factor H binding. Collectively
these data establish that the mechanism of serum resistance
associated with gonococcal strains that express Por1A is due
to binding of complement factor H to loop 5 of the porin.
This also represents the first demonstration of a second dis-
tinct factor H binding site on the surface of a single bacte-
rial subspecies.
 
Materials and Methods
 
Bacterial Strains.
 
23 strains of 
 
N
 
.
 
 gonorrhoeae
 
 (this paper; refer-
ences 2, 29–35) that were initially screened for factor H, total C3,
C3b, iC3b, and factor Bb binding in NHS are listed in Table 1.
Serological classification of the gonococcal strains was performed
using mAbs directed against Por (8). Subsequent measurements of
factor H binding to the following mutant gonococcal strains were
conducted using purified factor H instead of NHS (see below).
Isogenic strains that differed only in their porin structures were
constructed from strains FA19 (Por1A) and MS11 (Por1B; refer-
ence 27; see summary in the tabular portion of Fig. 2). Strain
FA6564 had Por1A porin reintroduced into an FA19 (Por1A)
background, whereas the isogenic pair FA6571 had Por1B porin
introduced into a Por1A background. Strain FA6616 had Por1B
porin reintroduced into an MS11 (Por1B) background, and the
isogenic mutant FA6611 had a Por1A porin introduced into a
Por1B background. Nine strains that contained Por1A/B porin
hybrid molecules (20) were used to localize the factor H–binding
region in the porin molecule. The hybrid strains were analyzed by
colony hybridization by using 10 oligonucleotides that were spe-
cific for either Por1A or Por1B gene sequences, to assess which
portions of the hybrid Por genes contained Por1A sequences and
which contained Por1B sequences (20).
 
Growth of Strains.
 
The 23 strains of 
 
N
 
.
 
 gonorrhoeae
 
 (Table 1),
and the Por1A/B hybrid mutant strains were grown for 13 h (5%
CO
 
2
 
, 37
 
°
 
C) on solid media supplemented with Isovitalex equiva-
lent (36). Nonpiliated, transparent organisms were lifted off the
plates with a sterile cotton swab, washed twice in HBSS, and re-
suspended in the same buffer for use in flow cytometry. This
method enabled us to screen a large number of strains at the same
time, to allow for a more meaningful and accurate interstrain
comparison. For all other experiments, gonococci were first
grown on solid media as described above, then inoculated into
liquid media and grown to mid-log phase (36).
 
Sera and Complement Reagents.
 
Pooled nonimmune NHS was
obtained from 11 healthy volunteers with no prior history of
gonococcal infection and used for initial screening of 23 gono-
coccal strains (Table 1). Human factor H was purified from hu-
man plasma to a final concentration of 1 mg/ml in PBS (37) and
used for binding studies with the Por1A/B hybrid and isogenic
mutant strains described above.
 
Antibodies.
 
Factor H bound to the organism surface was detected
in flow cytometry experiments using
 
 
 
affinity-purified rabbit poly-
clonal anti-factor H. This antibody was used at a final dilution of
1/100 of a stock solution of 0.26 mg/ml (7). mAbs C-5G and
C-3E, directed against human C3b and iC3b respectively (gifts of
 
Table 1.
 
Gonococcal Strains Surveyed for Factor H Binding
 
Strain Por subclass Reference
15253 1A 29, 30
24-1 1B 31
WG 1B 32
MS11 1B 33
FA19 1A 34
F62 1B 35
NRL no. 31772 1A 2
252 1B This paper
339063 1A This paper
273043 1A This paper
442089 1A This paper
401082 1A This paper
269041 1B This paper
156001 1B This paper
274045 1A This paper
255034 1B This paper
336062 1B This paper
256036 1B This paper
179008 1A This paper
374073 1A This paper
422083 1B This paper
398079 1B This paper
150002 1B This paper 
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Dr. Kyoko Iida, Takeda Chemical Industries, Ltd., Tsukuba, Ja-
pan; reference 38), and a mAb specific for the Bb neoantigen
fragment of human factor B (39; Quidel, San Diego, CA) were
used in whole cell ELISAs (see below) to monitor these comple-
ment components bound to gonococcal strains. mAb 2C3, that
binds the H.8 lipoprotein antigen that is present on all pathogenic
gonococcal strains (40, 41), was used to monitor the number of
organisms in the reaction mixtures, thereby permitting calcula-
tion of the density of the measured complement component on
gonococci. All mAbs were used at a final concentration of 25 
 
m
 
g/
ml in PBS. Total C3 bound to the organism surface was detected
with goat polyclonal anti-human C3 (Organon Teknika-Cappel,
Durham, NC; final concentration of specific antibody, 7 
 
m
 
g/ml
in PBS). All the above antibodies have been described in detail
previously (7). mAbs 3C8 and 5.51 that are specific for loop 5 of
Por1B (28) were used in dot-blot assays to characterize the
Por1A/B hybrid mutants. Only those hybrids (class 4 and class 9)
that contained Por1B loop 5 reacted with these mAbs; the class 7
and class 8 hybrids did not react and therefore were determined
to contain Por1A loop 5.
 
DNA Techniques and Porin Sequencing.
 
Genomic DNA was ex-
tracted from gonococcal strains 15253, 273043, 442089, 401082,
339063, and the class 4 hybrid using the phenol-chloroform ex-
traction method as described previously (42). The porin gene was
amplified from these templates by PCR using primers 33 and 34
that have been previously described (43, 44). After purification
of the PCR product, the region encompassing loop 5 was
sequenced using two internal primers, 5
 
9
 
-TTCGGGCAAAAA-
TCACAGC (sense oligonucleotide), and 5
 
9
 
-CGGAAGCGTACA-
GGGCATCA (anti-sense oligonucleotide), using an Applied Bio-
systems sequencer at the DNA core facility at Boston University.
 
Synthetic Peptides.
 
Synthetic peptides encompassing the puta-
tive exposed regions of the Por1A molecule were synthesized us-
ing tBOC protocols, as described (28). The loop 1, 3, and 5 pep-
tides used in this study correspond to the previously described
peptides 2, 3, and 4, respectively (28). The peptides were synthe-
sized with an NH
 
2
 
-terminal cysteine. Peptides were dissolved in
1% DMSO (vol/vol) in HBSS (to yield a 2 mg/ml stock solu-
tion). 50 
 
m
 
g and 100 
 
m
 
g of each peptide were used in flow cy-
tometry and bactericidal experiments respectively. An equivalent
amount of DMSO was included in all control reactions to ensure
that the results were not influenced by DMSO.
 
Flow Cytometry.
 
We used flow cytometry to quantitate bind-
ing of factor H to gonococci. This procedure has been described
in detail elsewhere (7). In brief, each sample tube contained 2 
 
3
 
10
 
8
 
 bacteria washed twice in HBSS and resuspended in 90 
 
m
 
l of
the same buffer. All buffers were passed through a 0.22-
 
m
 
m filter
to exclude particles that could interfere with flow cytometry.
Bacterial suspensions were incubated initially for 30 min with 10 
 
m
 
l
NHS or 5 
 
m
 
g purified human factor H (1 mg/ml in PBS). In cer-
tain experiments 50 
 
m
 
g of each synthetic peptide was used in the
suspension to attempt competition for factor H binding to bacte-
ria. Suspensions were centrifuged at 10,000 
 
g
 
 for 1 min, and pel-
lets were washed once with HBSS. Surface-bound factor H was
detected using anti-factor H antibody (incubated for 30 min at
room temperature), followed by FITC-labeled anti–rabbit IgG
(final dilution 1/100; Sigma Chemical Co.). The bacteria were
resuspended in 1 ml HBSS, applied immediately to a fluores-
cence-activated cell sorter (FACScan
 
Ò
 
; Becton Dickinson Immu-
nocytometry Systems, San Jose, CA), and 50,000 events were
counted.
 
ELISA.
 
C3b, iC3b, factor Bb, and total C3 bound to gono-
cocci opsonized with NHS were measured by whole cell ELISA (7).
 
Serum Bactericidal Assay.
 
Susceptibility of 23 gonococcal strains
to complement-mediated killing by nonimmune NHS was sur-
veyed with a serum bactericidal assay (final serum concentration
of 6.7%; reference 36; see Fig. 1). The isogenic porin mutant
strains (see Fig. 3) were subjected to NHS at a concentration of
33.3%. In bactericidal assays used to study the effect of the porin
loop peptides, the peptides (100 
 
m
 
g) were first added to the or-
ganism suspension, followed by the addition of NHS to a final
concentration of 33.3%. A higher concentration of NHS was
used here because strain FA19 is completely serum resistant,
whereas strain MS11 is only partially serum resistant (27). Rou-
tinely included as a control was NHS heat inactivated (56
 
8
 
C for
30 min) to ensure that reduction in colony counts at time zero
was not the result of agglutination.
 
Statistical Methods.
 
Factorial analysis of variance with Fisher’s
Protected Least Significant Difference (45) was performed using
the Statview 4.51 statistical analysis package (Abacus Concepts
Inc., Berkeley, CA).
 
Results
 
Identification of Por1A as the Acceptor Molecule for Factor H
on Nonsialylated N. gonorrhoeae.
 
Using flow cytometry we
screened 23 strains of 
 
N
 
.
 
 gonorrhoeae
 
 that had been incu-
bated with 10% NHS (30 min) for factor H binding. The
factor H binding observed after opsonization of organisms
lifted off solid media correlated well with factor H binding
to the same strains grown in liquid media on other occa-
sions. The forward scatter profiles did not indicate aggrega-
tion of organisms. Factor H may directly bind to the bacte-
rial surface, or may only be indirectly associated with the
bacteria through C3b that is bound to the bacterial outer
membrane. The 30-min time point was chosen to allow for
dissociation of any factor H bound only to C3b that even-
tually would be processed further to iC3b, thus providing a
better estimate of factor H directly bound to the organism
surface. As seen in Fig. 1, Por1A strains bound significantly
greater amounts of factor H as judged by a greater median
log
 
10
 
 fluorescence intensity (
 
P
 
 
 
5 
 
0.0125) on these strains. A
functional counterpart of factor H binding was examined
by measuring iC3b and C3b deposited on the organism
surface by whole-cell ELISA. We chose a 10-min time
point of opsonization because kinetic studies have shown
that maximal deposition of C3 components onto gono-
cocci occurs within 5 to 10 min of opsonization (46;
McQuillen et al., manuscript submitted for publication).
Por1A strains bound significantly less total C3 than Por1B
strains (optical density 
 
5 
 
0.449 
 
6
 
 0.092 vs. 0.917 
 
6
 
 0.123;
 
P 
 
5 
 
0.0089). Total iC3b bound was not significantly dif-
ferent between Por1A and Por1B strains (
 
P 
 
5 
 
0.5294, not
shown) but the total C3b as well as the factor Bb bound to
Por1A strains was significantly lower than for Por1B strains
(Fig. 1;
 
 P 
 
5 
 
0.0011 and
 
 P 
 
5 
 
0.0018, respectively). There-
fore, the ratio iC3b/(iC3b
 
1
 
C3b) was significantly higher
for Por1A strains (Fig. 1;
 
 P 
 
5 
 
0.0125), suggesting highly
efficient conversion of C3b to iC3b on these strains. These
observations also support dissociation of the alternative
pathway C3 convertase (C3b,Bb) by factor H, thereby lim-
iting the total amount of C3 deposited on the organism. 
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Collectively these data suggested that Por1A may act as a
gonococcal surface acceptor for factor H.
To confirm this hypothesis, we examined factor H bind-
ing to isogenic gonococcal mutant strains differing only in
their porin type. These isogenic mutants were generated
from strains FA19 (Por1A) and MS11 (Por1B; reference
27; tabular portion of Fig. 2). Pure factor H bound only to
strains that contained a Por1A porin (strains FA6564 and
FA6611), independent of the background (Fig. 2). This
suggests that the Por1A molecule is the acceptor for factor
H. The functional significance of factor H binding was es-
tablished by a serum bactericidal assay. Resistance to the
bactericidal activity of NHS (33.3%) correlated well with
the porin type of the strain (Fig. 3), with Por1A-bearing
strains FA6564 and FA6611 being completely serum
resistant, whereas Por1B containing strains FA6571 and
FA6616 being serum sensitive to the same degree.
 
Localization of the Specific Region of Por1A Where Factor H
Binds.
 
To localize the specific Por1A region necessary for
factor H binding, we studied the binding of pure factor H
to nine Por1A/B hybrid mutant strains (20) by flow cy-
tometry. The four hybrid strains that enabled us to localize
loop 5 as the region necessary for factor H binding are
shown in Fig. 4. The class 9 hybrid porin has been se-
quenced previously (47), and contains a Por1A sequence to
amino acid 144, where a crossover to MS11 (Por 1B) oc-
curs. Downstream reversion to a Por1A sequence takes
place in a conserved region between Por1A amino acids
208 and 213. Thus, the exposed regions of loops 4 and 5
are of a Por1B type, whereas all the other loops are of a
Por1A type. The class 4 hybrid consists of loops 1 through
4 that belong to Por1A, and loops 5 through 8 that belong
to Por1B; the crossover event occurs at amino acid 175 of
Por1A. mAbs 3C8 and 5.51, which are both specific for
Por1B loop 5, were used in dot-blot assays to further char-
acterize the structure of the hybrid strains (28). Both the
class 4 and class 9 hybrids bound to these mAbs, whereas
the class 7 and class 8 hybrids did not react (data not
shown). This confirmed that Por1B loop 5 was present in
the class 4 and class 9 hybrids, but not in the class 7 and
class 8 hybrids. The class 9 hybrid did not bind factor H,
which narrowed down the binding region to loops 4 and 5.
The class 4 hybrid did not bind factor H either, and there-
fore ruled out Por1A loop 4 as the factor H–binding re-
gion. The factor H binding domain in Por1A was nar-
rowed down to a region spanned by amino acids 175 and
Figure 1. Binding of factor H, C3b, and factor Bb to gonococci. 23
strains (10 Por1A, 13 Por1B; Table 1) of Neisseria gonorrhoeae were incu-
bated in 10% nonimmune NHS (30 min for factor H binding, and 10 min
for other complement components). Factor H binding was measured by
flow cytometry and is expressed as median log10 fluorescence. Because
this was a screening survey, factor H measurement was obtained once for
each strain and several strains were measured twice to control for poten-
tial experimental variation. Total C3, C3b, iC3b, and Bb were measured
by ELISA (duplicate experiments); data (C3b and Bb) are expressed as op-
tical density. The ratio of iC3b/(iC3b1C3b) was calculated and is also
shown. All data shown represent mean 6 SEM; significance was calcu-
lated by factorial analysis of variance with Fisher’s Protected Least Signifi-
cant Difference (45).
Figure 2. Binding of purified factor H (5 mg) to isogenic porin mutant
strains, measured by flow cytometry (one representative experiment of
two performed). Strain FA6564 (Por1A porin in a Por1A background)
bound factor H, while its isogenic mutant FA6571, differing only in the
porin molecule present (Por1B), did not. Similarly, FA6616 (Por1B porin
type in a Por1B background) did not bind factor H, while its isogenic pair
FA6611 (Por1A porin type in a Por1B background) bound factor H.
Thus, factor H binds only to strains bearing the Por1A subclass, indepen-
dent of the background. 
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208. The only exposed region in this part of the Por1A
molecule was loop 5. Thus, it was inferred that Por1A loop
5 was essential for factor H binding. This is further sup-
ported by the fact that the class 7 and class 8 hybrids, both
of which contain Por1A loop 5, bound factor H (Fig. 4).
Results obtained with five other Por1A/B hybrid strains
were consistent with those obtained above; only those hy-
brids that contained the fifth Por1A loop bound factor H
(data not shown).
To confirm that loop 5 was the factor H–binding region
in Por1A by a second independent method, we used a syn-
thetic 25-mer peptide that encompassed the putative ex-
posed region of Por1A loop 5 to inhibit the binding of pu-
rified factor H to strain FA6564. The amino acid sequence
of the loop 5 peptide is CVQYAGFYKRHSYTTEKH-
QVHRLV. The segment that corresponds to the surface
exposed region is underlined (amino acids 179–187). Two
other 25-mer peptides encompassing the exposed regions
of Por1A loop 1 and loop 3 were used as controls to impart
specificity to the assay (28). 50 
 
m
 
g of each peptide was used
to inhibit the binding of 5 
 
m
 
g of purified factor H. Only
the loop 5 peptide was able to inhibit factor H binding to
FA6564 to any significant degree (Fig. 5), validating the
fact that loop 5 is the factor H binding region in Por1A.
The six COOH-terminal amino acids in the loop 5 peptide
are unlikely to be relevant in binding of fH because they
are identical to this region in the Por1B structure.
Using the Por1A loop 5 peptide, we next attempted to
inhibit fH binding to five additional Por1A strains (15253,
Figure 3. Functional significance of factor H binding. Isogenic porin
mutant strains were subjected to the bactericidal action of 33% NHS.
Strains bearing a Por1B molecule (FA6571 and FA6616) were susceptible
to killing by NHS, while those that did not (FA6564 and FA6611) re-
sisted killing. This effect was independent of the background structure of
the strains. Data shown represent mean 6 SD of duplicate experiments.
Figure 4. The specific porin
loop of Por1A that binds factor
H was determined by incubating
factor H (5 mg) with Por1A/B
hybrid strains (20) followed by
flow cytometry (data shown here
for four hybrid strains; one repre-
sentative experiment of two per-
formed). The grey shaded area
indicates the location of loop 5.
Only those mutants that dis-
played a region that contained
loop 5 of the Por1A molecule
bound factor H, thus establishing
this as the Por region required
for factor H binding. The dotted
line within the Por1A molecule
represents the amino acid seg-
ment (present in Por1B of MS11)
that is deleted in Por1A of FA19. 
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273043, 442089, 401082, and 339063) that directly bound
pure fH. We were unable to demonstrate inhibition of fH
binding to any of these strains with this peptide. In each
case the sequence of putative surface exposed region of the
Por loop 5 had an amino acid sequence of RHNYTTEKH
(amino acids 179–187). This differed from the exposed re-
gion of loop 5 of FA6564 (RHSYTTEKH), where an Asn
residue replaces Ser at amino acid 181 (underlined).
 
Functional Correlation of Por1A Loop 5 Binding of Factor H.
 
To evaluate the functional impact of factor H binding to se-
rum resistant strain FA6564 (a strain completely resistant to
NHS), we attempted to block binding of factor H to the or-
ganism in the presence of NHS. A bactericidal assay was per-
formed using strain FA6564 that was first suspended in buffer
containing (or lacking) loop 5 peptide (100 
 
m
 
g), then com-
bined with NHS (final concentration 33.3%). Having previ-
ously established that only loop 5 peptide inhibited factor H
binding to the organism, we used only loop 1 peptide as a
control in this experiment. Additional controls included or-
ganisms incubated with NHS alone, loop 5 peptide alone,
heat-inactivated NHS plus loop 5 peptide, and NHS plus
loop 1 peptide. Killing in the presence of the peptides was
compared with killing at the corresponding time point with
NHS alone (percentage killing, Fig. 6). The reaction mixture
containing NHS and loop 5 peptide showed 37% killing
even at time zero, which increased to 52% at 30 min. No
significant killing was seen under any other conditions of in-
cubation, including NHS alone at either time point. Loop 5
peptide did not deplete hemolytic complement as evidenced
by the ability of NHS plus loop 5 peptide to lyse sensitized
sheep erythrocytes. Similar results were obtained when loop
5 peptide was preincubated with NHS (30 min on ice) be-
fore incubation with the organisms (48% killing at time zero
and 66% killing at 30 min). The addition of loop 5 peptide
presumably prevented factor H (in NHS) from binding to
the organisms. This in turn converted strain FA6564 to a
complement-activating surface that resulted in killing of this
strain. These data underscore the importance of factor H in
mediating serum resistance.
 
Discussion
 
The association between local genital inflammation ob-
served during infection with 
 
Neisseria gonorrhoeae and the
degree of resistance to serum killing is well established (1).
The several molecular mechanisms responsible for this rela-
tionship have begun to be delineated over the past decade
and a half. Isolates that are sensitive to killing by NHS in
vitro can be converted to a resistant phenotype by sialyla-
tion of the terminal lactosyl residue of their LOS (5, 48).
Recent work in our laboratory demonstrated that presence
of this terminal sialic acid residue permits direct binding of
factor H, accounting for the resultant conversion to a resis-
tant phenotype (7). Factor H, a critical regulator of the al-
ternative complement pathway, acts as a cofactor for factor
I–mediated cleavage of C3b to iC3b and facilitates dissocia-
tion of Bb from the alternative pathway C3 convertase
(C3b,Bb; references 37, 49, 50). Functionally, the increased
binding of factor H to sialylated serum-sensitive gonococci
(7) results in complete conversion of C3b to iC3b on these
isolates and decreased total C3 binding (7; McQuillen, D.P.,
S. Gulati, S. Ram, A.K. Turner, D.B. Jani, T.C. Heeren,
and P.A. Rice, manuscript submitted for publication).
Although N. gonorrhoeae clearly can use sialylation as a
means to evade the bactericidal action of the complement
system, unquestionably there are additional mechanisms in-
volved in serum resistance. Strains isolated from patients
with DGI remain predominantly serum resistant in vitro
without the addition of CMP-NANA to the growth me-
dium (1, 3). In addition, gonococci expressing Por1A are
more commonly serum resistant and associated with DGI,
whereas those expressing Por1B are more frequently serum
sensitive and associated with PID (14). Factor H–binding
proteins that may contribute to pathogenicity have been
identified on several microorganisms. The M6 protein of
Streptococcus pyogenes selectively binds factor H and mediates
inactivation of surface bound C3b (21, 22). Yersinia entero-
colitica that express YadA protein bind factor H and degrade
surface bound C3b to iC3b faster than those not expressing
YadA protein (23). Finally, gp41 (25) and gp120 (26) gly-
coproteins of human immunodeficiency virus 1 have been
shown to bind factor H. Recombinant gp120 coated on
the surface of CD4 cells also mediates cleavage of C3b (24).
We undertook this study to define whether a similar mech-
anism was responsible for the observed association of gono-
coccal Por1A with serum resistance.
Initial screening of 23 clinical and laboratory isolates in-
dicated that nonsialylated gonococci that expressed Por1A
Figure 5. Synthetic 25-mer
peptides (50 mg each) correspond-
ing to three of the putative ex-
posed loops of the Por1A molecule
(28) were incubated with strain
FA6564 followed by addition of
factor H (5 mg). Factor H binding
was measured by flow cytometry
(one representative experiment of
two performed). Only the peptide
corresponding to loop 5 inhibited
factor H binding, providing addi-
tional proof that loop 5 of Por1A is
critical for factor H binding.677 Ram et al.
bound more factor H in NHS than did gonococci express-
ing Por1B (P 5 0.0125; Fig. 1). Functionally, this resulted
in increased conversion of C3b to iC3b manifested as an
increase in the iC3b/(iC3b1C3b) ratio (P 5 0.0023; Fig.
1) and decreased susceptibility to killing by NHS of Por1A
strains (Fig. 3). Sialylation occurs to a variable degree in
vivo (40), perhaps as a result of sialidases secreted by other
organisms that may be present in genital secretions (51–53).
Under such conditions, the presence of a second binding
target for factor H would confer protection against com-
plement-mediated killing in the desialylated state.
Por1A was determined to be the target for factor H by
the use of isogenic gonococcal strains differing only in their
porin molecules. Fig. 2 demonstrates that only those strains
containing a Por1A porin molecule bound factor H, inde-
pendent of the background of the strain. Factor H binding
correlated well with an increased resistance to the bacteri-
cidal action of NHS (Fig. 3). The moderate degree of se-
rum resistance observed with these Por1B strains can prob-
ably be explained by the fact that both parent strains bind
significant amounts of C4b-binding protein (our un-
published observations). A prior study demonstrated that
FA6616 was almost completely killed (,10% survivors) by
30% serum, whereas 30% of FA6571 colonies survived at
this concentration of serum (27). The differences in the
sensitivities between FA6616 and FA6571 that were ob-
served in the earlier study using 30% serum (27) were not
seen in our bactericidal assay at this concentration, but
were evident when we used 66.7% NHS (data not shown).
At this higher serum concentration, z40% of FA6571 col-
onies survived, whereas ,10% of FA6616 colonies sur-
vived, consistent with results of the earlier study. A possible
explanation is a difference in the bactericidal method used
in the two studies. In the current study, z2,000 CFU of N.
gonorrhoeae were incubated with 33% serum, whereas in the
previous study, only 200–300 CFU were exposed to the
effects of 30% serum. This may have permitted more com-
plete and efficient opsonization in the earlier study, due to
greater numbers of C3 molecules present per organism, an
effect observed with erythrocytes (46). At a serum concen-
tration of 66.7%, the ratio of C3 to organisms more closely
approximated the opsonization conditions of the prior
study. Finally, incubation of purified factor H with the hy-
brid strains (20) indicated that only those mutants that con-
tained a region spanning loop 5 of Por1A bound factor H
(Fig. 4). All of the porin hybrid strains in this study are hy-
persusceptible to the killing activity of NHS (27). This may
explain the extreme rarity of such strains in nature (54), al-
though Por1A/B hybrids can be isolated in vitro after
DNA transformation (55). Therefore, we could not per-
form bactericidal assays to correlate factor H binding with
serum resistance of these Por1A/B hybrid strains.
Specificity of factor H binding was established by inhibi-
tion of purified factor H binding with a synthetic peptide
corresponding to Por1A loop 5 (28). Killing of FA6564 in
NHS was observed only in the presence of this peptide,
thereby confirming functional specificity of factor H bind-
ing. The effects of inhibiting the binding of factor H to
strain FA6564 when incubated with 33.3% NHS are seen
in Fig. 6. These results suggested almost immediate deposi-
tion of C3b and insertion of membrane attack complex, re-
sulting in impaired viability of the organism, which was
manifested as a reduction in colony counts (when com-
pared with the same number of organisms incubated with
NHS alone) at time zero as well as at 30 min. Control ex-
periments ensured that this reduction in colony counts was
the result of immediate killing and not of agglutination.
This degree of killing is impressive because strain FA6564 is
completely resistant to the bactericidal activity of even 66%
NHS (data not shown). FA6564 also binds C4b-binding
protein (our unpublished data), which downregulates the
classical pathway (56). This effect may protect the organism
against complete killing when factor H binding to the or-
ganism is inhibited with the Por1A loop 5 peptide. Finally,
the sequence of loop 5 of Por1A in strain FA19 (27) lacks
the chymotrypsin cleavage site (9) present in loop 5 of
Por1B in strain MS11 (20). The exposed amino acid se-
quence of loop 5 in Por1A (27) is relatively conserved
among strains of N. gonorrhoeae that express Por1A (by
GenBank search) and appeared to confer the ability to bind
factor H. The inability of the FA19 Por1A loop 5 peptide,
even when used at a 500-fold molar excess, to inhibit fH
binding to Por1A strains that express a different loop 5 se-
quence may be because the porin molecules with different
sequences bind to distinct, or separate, regions on fH.
Taken together, these data establish that the serum resis-
tance associated with gonococcal strains expressing Por1A
results from binding of complement factor H to loop 5 of
Figure 6. Functional importance of factor H in determining serum re-
sistance. An inhibition serum bactericidal assay was performed. 100 mg of
25-mer peptides corresponding to Por1A loop 1 and loop 5 were added
to the organisms (FA6564) before addition of NHS. Killing in the pres-
ence of the peptides was compared with killing at the corresponding time
point with NHS alone (results of duplicate experiments shown, mean 6
SD). Significant killing (35%) was seen even at time zero in the presence
of loop 5 peptide, which increased to 50% at 30 min. No killing was ob-
served with the loop 5 peptide in the absence of NHS, or with loop 1
peptide in the presence of NHS. Data shown represent mean 6 SD of
duplicate experiments.678 Factor H Binding to Por1A Loop 5 Mediates Stable Serum Resistance in Gonococci
the porin. Based on prior published gonococcal Por1A se-
quences and the sequences in this study we have derived a
consensus sequence for fH binding, which is RH-[SN]-
[YF]-TTEKH. These data also represent the first demon-
stration of a second, distinct factor H binding site on the
surface of a single bacterial subspecies.
Gonococcal porin is universally expressed and undergoes
minimal antigenic variation (10). These properties have led
to the intense investigation of the porin molecule as a po-
tential vaccine candidate. Two previous studies, which
used porin as an immunogen, demonstrated that the Por1A
molecule did not elicit as potent an immune response as
Por1B (47, 57, 58). Subsequently, the same synthetic pep-
tides that were used in this study were used to elicit an im-
mune response in rabbits. Interestingly, the Por1A loop 5
peptide elicited an antibody response in only one of two
immunized rabbits, despite the prediction that this loop
was likely to be highly immunogenic (28). In addition, the
antibody directed against this loop was not bactericidal.
These phenomena have not been fully explained. In con-
trast, the other Por1A peptides tested elicited a good bacte-
ricidal antibody response. Because loop 5 is highly con-
served across Por1A strains generally (GenBank search), the
construction of an effective porin vaccine may require an
immune response that nullifies binding of complement
downregulators such as factor H (and perhaps C4b-binding
protein, as seen in our preliminary unpublished data) to
these Por1A sequences in order to permit a beneficial effect
of immune antibody.
Although the binding of factor H is critical in mediating
serum resistance of most strains of N. gonorrhoeae, certain
non-sialylated serum resistant strains exist that do not bind
factor H, yet bind a significant amount of C3b (our unpub-
lished observations). Other mechanisms such as blocking
antibodies, which can block killing while activating com-
plement (59, 60), or regulation of membrane attack com-
plex insertion may be important in mediating serum resis-
tance of these strains.
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